“Pfizer” expects sales for the whole year of 2021 to range between 44.4 and 46.4 billion dollars, in addition to sales. Fertilization “Kofid 19”.
Earlier, the Morgan Stanley Foundation, which specializes in financial and investment services, indicated that Pfizer could achieve revenues of up to $ 19 billion from selling its vaccine in 2021 alone, in addition to the $ 975 million it would collect from the same source this year.
Analysts also expected, “Morgan Stanley” that “Pfizer” will raise 9.3 billion dollars from the sale of the vaccine against “Covid 19”, in consolidated profits in the next two years 2022 and 2023.
The promising results of the vaccine were reflected Corona On the shares of “Pfizer” and “Biontech”, as the share price of the first rose this year by 12%, while the shares of the second achieved a growth of about 300%, which prompted the market value of $ 30 billion.
On the other hand, the news about Moderna’s development of its own anti-epidemic vaccine helped raise the company’s market value to $ 62 billion, after its shares jumped 700 percent in 2020.
According to the expectations of experts from the financial services institution, “Golman Sachs”, “Moderna“It will make $ 13.2 billion next year, in revenue, for a vaccine that is awaiting approval from the US Food and Drug Administration.